Roble, Belko & Company, Inc Biomarin Pharmaceutical Inc Transaction History

Roble, Belko & Company, Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 10, 2020	SELL	$79.55 - $124.22 $16,307 - $25,465	-205 Closed	0 $0
Q2 2018 Aug 08, 2018	SELL	$76.01 - $99.03 $48,114 - $62,685	-633 Reduced 75.54%	205 $19,000
Q1 2018 May 14, 2018	BUY	$77.67 - $92.63 $18,485 - $22,045	238 Added 39.67%	838 $68,000
Q4 2017 Jan 30, 2018	BUY	$80.76 - $95.13 $48,456 - $57,078	600	600 $54,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Roble, Belko & Company, Inc, based on Form 13F filings with the SEC.

Stay updated on Roble, Belko & Company, Inc with notifications on news.